Summary

The global Angiogenesis Modulators market size is predicted to grow from US$ 19369 million in 2025 to US$ 29340 million in 2032; it is expected to grow at a CAGR of 6.1% from 2026 to 2032.
Angiogenesis Modulators are pharmaceutical or biologically active agents that regulate the formation, maturation, permeability, and regression of new blood vessels, with commercially marketed products currently dominated by inhibitory therapies. Their physical presentation varies by molecular modality and includes sterile clear solutions in single-use vials or prefilled syringes for intravitreal or intravenous administration, as well as oral tablets or capsules for systemic therapy. Structurally, the category mainly covers: biologics that bind VEGF-A, VEGF-B, PlGF, or dual pathways such as Ang-2/VEGF-A, including monoclonal antibodies and fusion proteins; small-molecule kinase inhibitors that block VEGFR1/2/3 and related signaling pathways; and a much smaller group of pro-angiogenic candidates still concentrated in development or niche clinical use. Their mechanism is to modulate endothelial-cell proliferation, migration, tube formation, vascular leakage, and vessel survival, thereby reshaping local blood supply and disease microenvironment. Current suppliers are primarily large pharmaceutical manufacturers, biosimilar developers, and specialist biopharma companies with capabilities in biologics manufacturing, sterile fill-finish, or targeted small-molecule production. Major application scenarios include oncology, neovascular retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. In practical market terms, the commercial value of Angiogenesis Modulators is overwhelmingly concentrated in anti-angiogenic products.
Over recent years, the commercial focus of Angiogenesis Modulators has continued to shift toward segments characterized by high barriers to entry, repeated dosing, and clearer reimbursement pathways. The strongest opportunities are coming from next-generation ophthalmic anti-VEGF therapies, expansion of oncology combination regimens, and growing biosimilar penetration. In ophthalmology, faricimab, high-dose aflibercept, and multiple aflibercept and ranibizumab biosimilars are reinforcing a competitive logic centered on longer dosing intervals, improved adherence, and lower payer burden. In oncology, VEGF/VEGFR inhibitors are increasingly positioned not only as standalone anti-vascular agents but also as backbone components in combinations with immunotherapy, chemotherapy, PARP inhibitors, and locoregional treatment. At the same time, population aging is enlarging the patient pool for wet AMD, DME, and RVO-related disease, while rising cancer prevalence and longer treatment duration continue to support demand. Growth therefore comes not only from new molecules, but also from formulation upgrades, prefilled delivery systems, regional access expansion, hospital switching, and reimbursement optimization.
The challenges and restraints are equally visible. First, competition in mature angiogenesis-related indications is already intense, with originator products facing pressure from both biosimilars and same-class competitors, leading to sustained pricing and tender pressure. Second, the benefit of anti-angiogenic therapy remains highly indication-specific and dependent on line of therapy and combination design, while long-term use is constrained by resistance, variable efficacy, and safety management issues such as hypertension, bleeding, proteinuria, thrombosis, impaired wound healing, and intraocular inflammation. Third, even in large ophthalmology markets, conversion dynamics depend heavily on specialist prescribing behavior, injection burden, real-world tolerability, and reimbursement policy; in oncology, usage is strongly shaped by guideline position, evidence quality in combination regimens, and payer negotiations. Fourth, the pro-angiogenic side still has limited commercial conversion, meaning that although the topic name covers all “modulators,” large-scale recurring revenue remains overwhelmingly concentrated in the inhibitory side.
Downstream demand is moving in three clear directions. The first is a shift from simple efficacy toward durability, lower injection frequency, and better fit with outpatient workflow, which is accelerating the move from conventional monoclonal antibodies toward bispecific antibodies, high-dose fusion proteins, and longer-acting delivery approaches in ophthalmology. The second is a transition from single-pathway targeting to use as a mechanistic module within combination therapy, especially in liver cancer, colorectal cancer, renal cell carcinoma, and lung cancer, where anti-VEGF/VEGFR therapies increasingly function as foundational partners in broader regimens. The third is a move from originator-dominated markets to multi-supplier systems. As biosimilars enter, hospitals and payers become more sensitive to access, budget control, sterile manufacturing quality, cold-chain reliability, and real-world evidence. Future growth will therefore not be driven by volume alone, but by a reallocation of share according to durability, affordability, supply reliability, and evidence strength.
LP Information, Inc. (LPI) ' newest research report, the “Angiogenesis Modulators Industry Forecast” looks at past sales and reviews total world Angiogenesis Modulators sales in 2025, providing a comprehensive analysis by region and market sector of projected Angiogenesis Modulators sales for 2026 through 2032. With Angiogenesis Modulators sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiogenesis Modulators industry.
This Insight Report provides a comprehensive analysis of the global Angiogenesis Modulators landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiogenesis Modulators portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Angiogenesis Modulators market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiogenesis Modulators and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiogenesis Modulators.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiogenesis Modulators market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
Segmentation by Mechanism Direction:
Anti-angiogenic Modulators
Pro-angiogenic Modulators
Bidirectional or Context-dependent Modulators
Others
Segmentation by Target Breadth:
Single-target Modulators
Dual-target Modulators
Multi-target Modulators
Others
Segmentation by Application:
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Roche
Regeneron
Bayer
Novartis
Eli Lilly
Pfizer
Eisai
Exelixis
Takeda
HUTCHMED
Amgen
Sandoz
Biocon Biologics
Celltrion
Samsung Bioepis
Biogen
Dr. Reddy’s Laboratories
Hetero
Intas Pharmaceuticals
AVEO Oncology
Innovent Biologics
Shanghai Henlius
Qilu Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Boan Biotech
Chengdu Kanghong Pharmaceutical Group
Genentech
Samsung Bioepis / Biogen
Sandoz / CIMERLI current business
Dr. Reddy’s / Versavo
Biocon / KRABEVA
Key Questions Addressed in this Report
What is the 10-year outlook for the global Angiogenesis Modulators market?
What factors are driving Angiogenesis Modulators market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiogenesis Modulators market opportunities vary by end market size?
How does Angiogenesis Modulators break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Angiogenesis Modulators Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Angiogenesis Modulators by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Angiogenesis Modulators by Country/Region, 2021, 2025 & 2032
2.2 Angiogenesis Modulators Segment by Type
2.2.1 Angiogenesis Inhibitors
2.2.2 Angiogenesis Stimulators
2.2.3 Angiogenin
2.2.4 Others
2.2.5 Angiogenesis Modulators Sales by Type
2.2.5.1 Global Angiogenesis Modulators Sales Market Share by Type (2021-2026)
2.2.5.2 Global Angiogenesis Modulators Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Angiogenesis Modulators Sale Price by Type (2021-2026)
2.3 Angiogenesis Modulators Segment by Mechanism Direction
2.3.1 Anti-angiogenic Modulators
2.3.2 Pro-angiogenic Modulators
2.3.3 Bidirectional or Context-dependent Modulators
2.3.4 Others
2.3.5 Angiogenesis Modulators Sales by Mechanism Direction
2.3.5.1 Global Angiogenesis Modulators Sales Market Share by Mechanism Direction (2021-2026)
2.3.5.2 Global Angiogenesis Modulators Revenue and Market Share by Mechanism Direction (2021-2026)
2.3.5.3 Global Angiogenesis Modulators Sale Price by Mechanism Direction (2021-2026)
2.4 Angiogenesis Modulators Segment by Target Breadth
2.4.1 Single-target Modulators
2.4.2 Dual-target Modulators
2.4.3 Multi-target Modulators
2.4.4 Others
2.4.5 Angiogenesis Modulators Sales by Target Breadth
2.4.5.1 Global Angiogenesis Modulators Sales Market Share by Target Breadth (2021-2026)
2.4.5.2 Global Angiogenesis Modulators Revenue and Market Share by Target Breadth (2021-2026)
2.4.5.3 Global Angiogenesis Modulators Sale Price by Target Breadth (2021-2026)
2.5 Angiogenesis Modulators Segment by Application
2.5.1 Breast Cancer
2.5.2 Colorectal Cancer
2.5.3 Lung Cancer
2.5.4 Prostate Cancer
2.5.5 Others
2.5.6 Angiogenesis Modulators Sales by Application
2.5.6.1 Global Angiogenesis Modulators Sale Market Share by Application (2021-2026)
2.5.6.2 Global Angiogenesis Modulators Revenue and Market Share by Application (2021-2026)
2.5.6.3 Global Angiogenesis Modulators Sale Price by Application (2021-2026)
3 Global by Company
3.1 Global Angiogenesis Modulators Breakdown Data by Company
3.1.1 Global Angiogenesis Modulators Annual Sales by Company (2021-2026)
3.1.2 Global Angiogenesis Modulators Sales Market Share by Company (2021-2026)
3.2 Global Angiogenesis Modulators Annual Revenue by Company (2021-2026)
3.2.1 Global Angiogenesis Modulators Revenue by Company (2021-2026)
3.2.2 Global Angiogenesis Modulators Revenue Market Share by Company (2021-2026)
3.3 Global Angiogenesis Modulators Sale Price by Company
3.4 Key Manufacturers Angiogenesis Modulators Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Angiogenesis Modulators Product Location Distribution
3.4.2 Players Angiogenesis Modulators Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Angiogenesis Modulators by Geographic Region
4.1 World Historic Angiogenesis Modulators Market Size by Geographic Region (2021-2026)
4.1.1 Global Angiogenesis Modulators Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Angiogenesis Modulators Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Angiogenesis Modulators Market Size by Country/Region (2021-2026)
4.2.1 Global Angiogenesis Modulators Annual Sales by Country/Region (2021-2026)
4.2.2 Global Angiogenesis Modulators Annual Revenue by Country/Region (2021-2026)
4.3 Americas Angiogenesis Modulators Sales Growth
4.4 APAC Angiogenesis Modulators Sales Growth
4.5 Europe Angiogenesis Modulators Sales Growth
4.6 Middle East & Africa Angiogenesis Modulators Sales Growth
5 Americas
5.1 Americas Angiogenesis Modulators Sales by Country
5.1.1 Americas Angiogenesis Modulators Sales by Country (2021-2026)
5.1.2 Americas Angiogenesis Modulators Revenue by Country (2021-2026)
5.2 Americas Angiogenesis Modulators Sales by Type (2021-2026)
5.3 Americas Angiogenesis Modulators Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Angiogenesis Modulators Sales by Region
6.1.1 APAC Angiogenesis Modulators Sales by Region (2021-2026)
6.1.2 APAC Angiogenesis Modulators Revenue by Region (2021-2026)
6.2 APAC Angiogenesis Modulators Sales by Type (2021-2026)
6.3 APAC Angiogenesis Modulators Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Angiogenesis Modulators by Country
7.1.1 Europe Angiogenesis Modulators Sales by Country (2021-2026)
7.1.2 Europe Angiogenesis Modulators Revenue by Country (2021-2026)
7.2 Europe Angiogenesis Modulators Sales by Type (2021-2026)
7.3 Europe Angiogenesis Modulators Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Angiogenesis Modulators by Country
8.1.1 Middle East & Africa Angiogenesis Modulators Sales by Country (2021-2026)
8.1.2 Middle East & Africa Angiogenesis Modulators Revenue by Country (2021-2026)
8.2 Middle East & Africa Angiogenesis Modulators Sales by Type (2021-2026)
8.3 Middle East & Africa Angiogenesis Modulators Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Angiogenesis Modulators
10.3 Manufacturing Process Analysis of Angiogenesis Modulators
10.4 Industry Chain Structure of Angiogenesis Modulators
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Angiogenesis Modulators Distributors
11.3 Angiogenesis Modulators Customer
12 World Forecast Review for Angiogenesis Modulators by Geographic Region
12.1 Global Angiogenesis Modulators Market Size Forecast by Region
12.1.1 Global Angiogenesis Modulators Forecast by Region (2027-2032)
12.1.2 Global Angiogenesis Modulators Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Angiogenesis Modulators Forecast by Type (2027-2032)
12.7 Global Angiogenesis Modulators Forecast by Application (2027-2032)
13 Key Players Analysis
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Angiogenesis Modulators Product Portfolios and Specifications
13.1.3 Roche Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Regeneron
13.2.1 Regeneron Company Information
13.2.2 Regeneron Angiogenesis Modulators Product Portfolios and Specifications
13.2.3 Regeneron Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Regeneron Main Business Overview
13.2.5 Regeneron Latest Developments
13.3 Bayer
13.3.1 Bayer Company Information
13.3.2 Bayer Angiogenesis Modulators Product Portfolios and Specifications
13.3.3 Bayer Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bayer Main Business Overview
13.3.5 Bayer Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Angiogenesis Modulators Product Portfolios and Specifications
13.4.3 Novartis Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Angiogenesis Modulators Product Portfolios and Specifications
13.5.3 Eli Lilly Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 Pfizer
13.6.1 Pfizer Company Information
13.6.2 Pfizer Angiogenesis Modulators Product Portfolios and Specifications
13.6.3 Pfizer Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Pfizer Main Business Overview
13.6.5 Pfizer Latest Developments
13.7 Eisai
13.7.1 Eisai Company Information
13.7.2 Eisai Angiogenesis Modulators Product Portfolios and Specifications
13.7.3 Eisai Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Eisai Main Business Overview
13.7.5 Eisai Latest Developments
13.8 Exelixis
13.8.1 Exelixis Company Information
13.8.2 Exelixis Angiogenesis Modulators Product Portfolios and Specifications
13.8.3 Exelixis Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Exelixis Main Business Overview
13.8.5 Exelixis Latest Developments
13.9 Takeda
13.9.1 Takeda Company Information
13.9.2 Takeda Angiogenesis Modulators Product Portfolios and Specifications
13.9.3 Takeda Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Takeda Main Business Overview
13.9.5 Takeda Latest Developments
13.10 HUTCHMED
13.10.1 HUTCHMED Company Information
13.10.2 HUTCHMED Angiogenesis Modulators Product Portfolios and Specifications
13.10.3 HUTCHMED Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 HUTCHMED Main Business Overview
13.10.5 HUTCHMED Latest Developments
13.11 Amgen
13.11.1 Amgen Company Information
13.11.2 Amgen Angiogenesis Modulators Product Portfolios and Specifications
13.11.3 Amgen Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Amgen Main Business Overview
13.11.5 Amgen Latest Developments
13.12 Sandoz
13.12.1 Sandoz Company Information
13.12.2 Sandoz Angiogenesis Modulators Product Portfolios and Specifications
13.12.3 Sandoz Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Sandoz Main Business Overview
13.12.5 Sandoz Latest Developments
13.13 Biocon Biologics
13.13.1 Biocon Biologics Company Information
13.13.2 Biocon Biologics Angiogenesis Modulators Product Portfolios and Specifications
13.13.3 Biocon Biologics Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Biocon Biologics Main Business Overview
13.13.5 Biocon Biologics Latest Developments
13.14 Celltrion
13.14.1 Celltrion Company Information
13.14.2 Celltrion Angiogenesis Modulators Product Portfolios and Specifications
13.14.3 Celltrion Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Celltrion Main Business Overview
13.14.5 Celltrion Latest Developments
13.15 Samsung Bioepis
13.15.1 Samsung Bioepis Company Information
13.15.2 Samsung Bioepis Angiogenesis Modulators Product Portfolios and Specifications
13.15.3 Samsung Bioepis Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Samsung Bioepis Main Business Overview
13.15.5 Samsung Bioepis Latest Developments
13.16 Biogen
13.16.1 Biogen Company Information
13.16.2 Biogen Angiogenesis Modulators Product Portfolios and Specifications
13.16.3 Biogen Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Biogen Main Business Overview
13.16.5 Biogen Latest Developments
13.17 Dr. Reddy’s Laboratories
13.17.1 Dr. Reddy’s Laboratories Company Information
13.17.2 Dr. Reddy’s Laboratories Angiogenesis Modulators Product Portfolios and Specifications
13.17.3 Dr. Reddy’s Laboratories Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Dr. Reddy’s Laboratories Main Business Overview
13.17.5 Dr. Reddy’s Laboratories Latest Developments
13.18 Hetero
13.18.1 Hetero Company Information
13.18.2 Hetero Angiogenesis Modulators Product Portfolios and Specifications
13.18.3 Hetero Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Hetero Main Business Overview
13.18.5 Hetero Latest Developments
13.19 Intas Pharmaceuticals
13.19.1 Intas Pharmaceuticals Company Information
13.19.2 Intas Pharmaceuticals Angiogenesis Modulators Product Portfolios and Specifications
13.19.3 Intas Pharmaceuticals Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Intas Pharmaceuticals Main Business Overview
13.19.5 Intas Pharmaceuticals Latest Developments
13.20 AVEO Oncology
13.20.1 AVEO Oncology Company Information
13.20.2 AVEO Oncology Angiogenesis Modulators Product Portfolios and Specifications
13.20.3 AVEO Oncology Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 AVEO Oncology Main Business Overview
13.20.5 AVEO Oncology Latest Developments
13.21 Innovent Biologics
13.21.1 Innovent Biologics Company Information
13.21.2 Innovent Biologics Angiogenesis Modulators Product Portfolios and Specifications
13.21.3 Innovent Biologics Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 Innovent Biologics Main Business Overview
13.21.5 Innovent Biologics Latest Developments
13.22 Shanghai Henlius
13.22.1 Shanghai Henlius Company Information
13.22.2 Shanghai Henlius Angiogenesis Modulators Product Portfolios and Specifications
13.22.3 Shanghai Henlius Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 Shanghai Henlius Main Business Overview
13.22.5 Shanghai Henlius Latest Developments
13.23 Qilu Pharmaceutical
13.23.1 Qilu Pharmaceutical Company Information
13.23.2 Qilu Pharmaceutical Angiogenesis Modulators Product Portfolios and Specifications
13.23.3 Qilu Pharmaceutical Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 Qilu Pharmaceutical Main Business Overview
13.23.5 Qilu Pharmaceutical Latest Developments
13.24 Jiangsu Hengrui Pharmaceuticals
13.24.1 Jiangsu Hengrui Pharmaceuticals Company Information
13.24.2 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product Portfolios and Specifications
13.24.3 Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
13.24.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
13.25 Boan Biotech
13.25.1 Boan Biotech Company Information
13.25.2 Boan Biotech Angiogenesis Modulators Product Portfolios and Specifications
13.25.3 Boan Biotech Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 Boan Biotech Main Business Overview
13.25.5 Boan Biotech Latest Developments
13.26 Chengdu Kanghong Pharmaceutical Group
13.26.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.26.2 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product Portfolios and Specifications
13.26.3 Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.26.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
13.27 Genentech
13.27.1 Genentech Company Information
13.27.2 Genentech Angiogenesis Modulators Product Portfolios and Specifications
13.27.3 Genentech Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Genentech Main Business Overview
13.27.5 Genentech Latest Developments
13.28 Samsung Bioepis / Biogen
13.28.1 Samsung Bioepis / Biogen Company Information
13.28.2 Samsung Bioepis / Biogen Angiogenesis Modulators Product Portfolios and Specifications
13.28.3 Samsung Bioepis / Biogen Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 Samsung Bioepis / Biogen Main Business Overview
13.28.5 Samsung Bioepis / Biogen Latest Developments
13.29 Sandoz / CIMERLI current business
13.29.1 Sandoz / CIMERLI current business Company Information
13.29.2 Sandoz / CIMERLI current business Angiogenesis Modulators Product Portfolios and Specifications
13.29.3 Sandoz / CIMERLI current business Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 Sandoz / CIMERLI current business Main Business Overview
13.29.5 Sandoz / CIMERLI current business Latest Developments
13.30 Dr. Reddy’s / Versavo
13.30.1 Dr. Reddy’s / Versavo Company Information
13.30.2 Dr. Reddy’s / Versavo Angiogenesis Modulators Product Portfolios and Specifications
13.30.3 Dr. Reddy’s / Versavo Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.30.4 Dr. Reddy’s / Versavo Main Business Overview
13.30.5 Dr. Reddy’s / Versavo Latest Developments
13.31 Biocon / KRABEVA
13.31.1 Biocon / KRABEVA Company Information
13.31.2 Biocon / KRABEVA Angiogenesis Modulators Product Portfolios and Specifications
13.31.3 Biocon / KRABEVA Angiogenesis Modulators Sales, Revenue, Price and Gross Margin (2021-2026)
13.31.4 Biocon / KRABEVA Main Business Overview
13.31.5 Biocon / KRABEVA Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Angiogenesis Modulators Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Angiogenesis Modulators Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Angiogenesis Inhibitors
Table 4. Major Players of Angiogenesis Stimulators
Table 5. Major Players of Angiogenin
Table 6. Major Players of Others
Table 7. Global Angiogenesis Modulators Sales by Type (2021-2026) & (K Units)
Table 8. Global Angiogenesis Modulators Sales Market Share by Type (2021-2026)
Table 9. Global Angiogenesis Modulators Revenue by Type (2021-2026) & ($ million)
Table 10. Global Angiogenesis Modulators Revenue Market Share by Type (2021-2026)
Table 11. Global Angiogenesis Modulators Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Major Players of Anti-angiogenic Modulators
Table 13. Major Players of Pro-angiogenic Modulators
Table 14. Major Players of Bidirectional or Context-dependent Modulators
Table 15. Major Players of Others
Table 16. Global Angiogenesis Modulators Sales by Mechanism Direction (2021-2026) & (K Units)
Table 17. Global Angiogenesis Modulators Sales Market Share by Mechanism Direction (2021-2026)
Table 18. Global Angiogenesis Modulators Revenue by Mechanism Direction (2021-2026) & ($ million)
Table 19. Global Angiogenesis Modulators Revenue Market Share by Mechanism Direction (2021-2026)
Table 20. Global Angiogenesis Modulators Sale Price by Mechanism Direction (2021-2026) & (US$/Unit)
Table 21. Major Players of Single-target Modulators
Table 22. Major Players of Dual-target Modulators
Table 23. Major Players of Multi-target Modulators
Table 24. Major Players of Others
Table 25. Global Angiogenesis Modulators Sales by Target Breadth (2021-2026) & (K Units)
Table 26. Global Angiogenesis Modulators Sales Market Share by Target Breadth (2021-2026)
Table 27. Global Angiogenesis Modulators Revenue by Target Breadth (2021-2026) & ($ million)
Table 28. Global Angiogenesis Modulators Revenue Market Share by Target Breadth (2021-2026)
Table 29. Global Angiogenesis Modulators Sale Price by Target Breadth (2021-2026) & (US$/Unit)
Table 30. Global Angiogenesis Modulators Sale by Application (2021-2026) & (K Units)
Table 31. Global Angiogenesis Modulators Sale Market Share by Application (2021-2026)
Table 32. Global Angiogenesis Modulators Revenue by Application (2021-2026) & ($ million)
Table 33. Global Angiogenesis Modulators Revenue Market Share by Application (2021-2026)
Table 34. Global Angiogenesis Modulators Sale Price by Application (2021-2026) & (US$/Unit)
Table 35. Global Angiogenesis Modulators Sales by Company (2021-2026) & (K Units)
Table 36. Global Angiogenesis Modulators Sales Market Share by Company (2021-2026)
Table 37. Global Angiogenesis Modulators Revenue by Company (2021-2026) & ($ millions)
Table 38. Global Angiogenesis Modulators Revenue Market Share by Company (2021-2026)
Table 39. Global Angiogenesis Modulators Sale Price by Company (2021-2026) & (US$/Unit)
Table 40. Key Manufacturers Angiogenesis Modulators Producing Area Distribution and Sales Area
Table 41. Players Angiogenesis Modulators Products Offered
Table 42. Angiogenesis Modulators Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 43. New Products and Potential Entrants
Table 44. Market M&A Activity & Strategy
Table 45. Global Angiogenesis Modulators Sales by Geographic Region (2021-2026) & (K Units)
Table 46. Global Angiogenesis Modulators Sales Market Share Geographic Region (2021-2026)
Table 47. Global Angiogenesis Modulators Revenue by Geographic Region (2021-2026) & ($ millions)
Table 48. Global Angiogenesis Modulators Revenue Market Share by Geographic Region (2021-2026)
Table 49. Global Angiogenesis Modulators Sales by Country/Region (2021-2026) & (K Units)
Table 50. Global Angiogenesis Modulators Sales Market Share by Country/Region (2021-2026)
Table 51. Global Angiogenesis Modulators Revenue by Country/Region (2021-2026) & ($ millions)
Table 52. Global Angiogenesis Modulators Revenue Market Share by Country/Region (2021-2026)
Table 53. Americas Angiogenesis Modulators Sales by Country (2021-2026) & (K Units)
Table 54. Americas Angiogenesis Modulators Sales Market Share by Country (2021-2026)
Table 55. Americas Angiogenesis Modulators Revenue by Country (2021-2026) & ($ millions)
Table 56. Americas Angiogenesis Modulators Sales by Type (2021-2026) & (K Units)
Table 57. Americas Angiogenesis Modulators Sales by Application (2021-2026) & (K Units)
Table 58. APAC Angiogenesis Modulators Sales by Region (2021-2026) & (K Units)
Table 59. APAC Angiogenesis Modulators Sales Market Share by Region (2021-2026)
Table 60. APAC Angiogenesis Modulators Revenue by Region (2021-2026) & ($ millions)
Table 61. APAC Angiogenesis Modulators Sales by Type (2021-2026) & (K Units)
Table 62. APAC Angiogenesis Modulators Sales by Application (2021-2026) & (K Units)
Table 63. Europe Angiogenesis Modulators Sales by Country (2021-2026) & (K Units)
Table 64. Europe Angiogenesis Modulators Revenue by Country (2021-2026) & ($ millions)
Table 65. Europe Angiogenesis Modulators Sales by Type (2021-2026) & (K Units)
Table 66. Europe Angiogenesis Modulators Sales by Application (2021-2026) & (K Units)
Table 67. Middle East & Africa Angiogenesis Modulators Sales by Country (2021-2026) & (K Units)
Table 68. Middle East & Africa Angiogenesis Modulators Revenue Market Share by Country (2021-2026)
Table 69. Middle East & Africa Angiogenesis Modulators Sales by Type (2021-2026) & (K Units)
Table 70. Middle East & Africa Angiogenesis Modulators Sales by Application (2021-2026) & (K Units)
Table 71. Key Market Drivers & Growth Opportunities of Angiogenesis Modulators
Table 72. Key Market Challenges & Risks of Angiogenesis Modulators
Table 73. Key Industry Trends of Angiogenesis Modulators
Table 74. Angiogenesis Modulators Raw Material
Table 75. Key Suppliers of Raw Materials
Table 76. Angiogenesis Modulators Distributors List
Table 77. Angiogenesis Modulators Customer List
Table 78. Global Angiogenesis Modulators Sales Forecast by Region (2027-2032) & (K Units)
Table 79. Global Angiogenesis Modulators Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Americas Angiogenesis Modulators Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Americas Angiogenesis Modulators Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. APAC Angiogenesis Modulators Sales Forecast by Region (2027-2032) & (K Units)
Table 83. APAC Angiogenesis Modulators Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 84. Europe Angiogenesis Modulators Sales Forecast by Country (2027-2032) & (K Units)
Table 85. Europe Angiogenesis Modulators Revenue Forecast by Country (2027-2032) & ($ millions)
Table 86. Middle East & Africa Angiogenesis Modulators Sales Forecast by Country (2027-2032) & (K Units)
Table 87. Middle East & Africa Angiogenesis Modulators Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. Global Angiogenesis Modulators Sales Forecast by Type (2027-2032) & (K Units)
Table 89. Global Angiogenesis Modulators Revenue Forecast by Type (2027-2032) & ($ millions)
Table 90. Global Angiogenesis Modulators Sales Forecast by Application (2027-2032) & (K Units)
Table 91. Global Angiogenesis Modulators Revenue Forecast by Application (2027-2032) & ($ millions)
Table 92. Roche Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 93. Roche Angiogenesis Modulators Product Portfolios and Specifications
Table 94. Roche Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Roche Main Business
Table 96. Roche Latest Developments
Table 97. Regeneron Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 98. Regeneron Angiogenesis Modulators Product Portfolios and Specifications
Table 99. Regeneron Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Regeneron Main Business
Table 101. Regeneron Latest Developments
Table 102. Bayer Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 103. Bayer Angiogenesis Modulators Product Portfolios and Specifications
Table 104. Bayer Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Bayer Main Business
Table 106. Bayer Latest Developments
Table 107. Novartis Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 108. Novartis Angiogenesis Modulators Product Portfolios and Specifications
Table 109. Novartis Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Novartis Main Business
Table 111. Novartis Latest Developments
Table 112. Eli Lilly Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 113. Eli Lilly Angiogenesis Modulators Product Portfolios and Specifications
Table 114. Eli Lilly Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Eli Lilly Main Business
Table 116. Eli Lilly Latest Developments
Table 117. Pfizer Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 118. Pfizer Angiogenesis Modulators Product Portfolios and Specifications
Table 119. Pfizer Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Pfizer Main Business
Table 121. Pfizer Latest Developments
Table 122. Eisai Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 123. Eisai Angiogenesis Modulators Product Portfolios and Specifications
Table 124. Eisai Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Eisai Main Business
Table 126. Eisai Latest Developments
Table 127. Exelixis Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 128. Exelixis Angiogenesis Modulators Product Portfolios and Specifications
Table 129. Exelixis Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Exelixis Main Business
Table 131. Exelixis Latest Developments
Table 132. Takeda Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 133. Takeda Angiogenesis Modulators Product Portfolios and Specifications
Table 134. Takeda Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. Takeda Main Business
Table 136. Takeda Latest Developments
Table 137. HUTCHMED Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 138. HUTCHMED Angiogenesis Modulators Product Portfolios and Specifications
Table 139. HUTCHMED Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 140. HUTCHMED Main Business
Table 141. HUTCHMED Latest Developments
Table 142. Amgen Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 143. Amgen Angiogenesis Modulators Product Portfolios and Specifications
Table 144. Amgen Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 145. Amgen Main Business
Table 146. Amgen Latest Developments
Table 147. Sandoz Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 148. Sandoz Angiogenesis Modulators Product Portfolios and Specifications
Table 149. Sandoz Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 150. Sandoz Main Business
Table 151. Sandoz Latest Developments
Table 152. Biocon Biologics Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 153. Biocon Biologics Angiogenesis Modulators Product Portfolios and Specifications
Table 154. Biocon Biologics Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 155. Biocon Biologics Main Business
Table 156. Biocon Biologics Latest Developments
Table 157. Celltrion Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 158. Celltrion Angiogenesis Modulators Product Portfolios and Specifications
Table 159. Celltrion Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 160. Celltrion Main Business
Table 161. Celltrion Latest Developments
Table 162. Samsung Bioepis Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 163. Samsung Bioepis Angiogenesis Modulators Product Portfolios and Specifications
Table 164. Samsung Bioepis Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 165. Samsung Bioepis Main Business
Table 166. Samsung Bioepis Latest Developments
Table 167. Biogen Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 168. Biogen Angiogenesis Modulators Product Portfolios and Specifications
Table 169. Biogen Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 170. Biogen Main Business
Table 171. Biogen Latest Developments
Table 172. Dr. Reddy’s Laboratories Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 173. Dr. Reddy’s Laboratories Angiogenesis Modulators Product Portfolios and Specifications
Table 174. Dr. Reddy’s Laboratories Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 175. Dr. Reddy’s Laboratories Main Business
Table 176. Dr. Reddy’s Laboratories Latest Developments
Table 177. Hetero Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 178. Hetero Angiogenesis Modulators Product Portfolios and Specifications
Table 179. Hetero Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 180. Hetero Main Business
Table 181. Hetero Latest Developments
Table 182. Intas Pharmaceuticals Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 183. Intas Pharmaceuticals Angiogenesis Modulators Product Portfolios and Specifications
Table 184. Intas Pharmaceuticals Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 185. Intas Pharmaceuticals Main Business
Table 186. Intas Pharmaceuticals Latest Developments
Table 187. AVEO Oncology Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 188. AVEO Oncology Angiogenesis Modulators Product Portfolios and Specifications
Table 189. AVEO Oncology Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 190. AVEO Oncology Main Business
Table 191. AVEO Oncology Latest Developments
Table 192. Innovent Biologics Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 193. Innovent Biologics Angiogenesis Modulators Product Portfolios and Specifications
Table 194. Innovent Biologics Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 195. Innovent Biologics Main Business
Table 196. Innovent Biologics Latest Developments
Table 197. Shanghai Henlius Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 198. Shanghai Henlius Angiogenesis Modulators Product Portfolios and Specifications
Table 199. Shanghai Henlius Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 200. Shanghai Henlius Main Business
Table 201. Shanghai Henlius Latest Developments
Table 202. Qilu Pharmaceutical Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 203. Qilu Pharmaceutical Angiogenesis Modulators Product Portfolios and Specifications
Table 204. Qilu Pharmaceutical Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 205. Qilu Pharmaceutical Main Business
Table 206. Qilu Pharmaceutical Latest Developments
Table 207. Jiangsu Hengrui Pharmaceuticals Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 208. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Product Portfolios and Specifications
Table 209. Jiangsu Hengrui Pharmaceuticals Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 210. Jiangsu Hengrui Pharmaceuticals Main Business
Table 211. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 212. Boan Biotech Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 213. Boan Biotech Angiogenesis Modulators Product Portfolios and Specifications
Table 214. Boan Biotech Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 215. Boan Biotech Main Business
Table 216. Boan Biotech Latest Developments
Table 217. Chengdu Kanghong Pharmaceutical Group Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 218. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Product Portfolios and Specifications
Table 219. Chengdu Kanghong Pharmaceutical Group Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 220. Chengdu Kanghong Pharmaceutical Group Main Business
Table 221. Chengdu Kanghong Pharmaceutical Group Latest Developments
Table 222. Genentech Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 223. Genentech Angiogenesis Modulators Product Portfolios and Specifications
Table 224. Genentech Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 225. Genentech Main Business
Table 226. Genentech Latest Developments
Table 227. Samsung Bioepis / Biogen Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 228. Samsung Bioepis / Biogen Angiogenesis Modulators Product Portfolios and Specifications
Table 229. Samsung Bioepis / Biogen Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 230. Samsung Bioepis / Biogen Main Business
Table 231. Samsung Bioepis / Biogen Latest Developments
Table 232. Sandoz / CIMERLI current business Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 233. Sandoz / CIMERLI current business Angiogenesis Modulators Product Portfolios and Specifications
Table 234. Sandoz / CIMERLI current business Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 235. Sandoz / CIMERLI current business Main Business
Table 236. Sandoz / CIMERLI current business Latest Developments
Table 237. Dr. Reddy’s / Versavo Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 238. Dr. Reddy’s / Versavo Angiogenesis Modulators Product Portfolios and Specifications
Table 239. Dr. Reddy’s / Versavo Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 240. Dr. Reddy’s / Versavo Main Business
Table 241. Dr. Reddy’s / Versavo Latest Developments
Table 242. Biocon / KRABEVA Basic Information, Angiogenesis Modulators Manufacturing Base, Sales Area and Its Competitors
Table 243. Biocon / KRABEVA Angiogenesis Modulators Product Portfolios and Specifications
Table 244. Biocon / KRABEVA Angiogenesis Modulators Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 245. Biocon / KRABEVA Main Business
Table 246. Biocon / KRABEVA Latest Developments


List of Figures
Figure 1. Picture of Angiogenesis Modulators
Figure 2. Angiogenesis Modulators Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Angiogenesis Modulators Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Angiogenesis Modulators Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Angiogenesis Modulators Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Angiogenesis Modulators Sales Market Share by Country/Region (2025)
Figure 10. Angiogenesis Modulators Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Angiogenesis Inhibitors
Figure 12. Product Picture of Angiogenesis Stimulators
Figure 13. Product Picture of Angiogenin
Figure 14. Product Picture of Others
Figure 15. Global Angiogenesis Modulators Sales Market Share by Type in 2026
Figure 16. Global Angiogenesis Modulators Revenue Market Share by Type (2021-2026)
Figure 17. Product Picture of Anti-angiogenic Modulators
Figure 18. Product Picture of Pro-angiogenic Modulators
Figure 19. Product Picture of Bidirectional or Context-dependent Modulators
Figure 20. Product Picture of Others
Figure 21. Global Angiogenesis Modulators Sales Market Share by Mechanism Direction in 2026
Figure 22. Global Angiogenesis Modulators Revenue Market Share by Mechanism Direction (2021-2026)
Figure 23. Product Picture of Single-target Modulators
Figure 24. Product Picture of Dual-target Modulators
Figure 25. Product Picture of Multi-target Modulators
Figure 26. Product Picture of Others
Figure 27. Global Angiogenesis Modulators Sales Market Share by Target Breadth in 2026
Figure 28. Global Angiogenesis Modulators Revenue Market Share by Target Breadth (2021-2026)
Figure 29. Angiogenesis Modulators Consumed in Breast Cancer
Figure 30. Global Angiogenesis Modulators Market: Breast Cancer (2021-2026) & (K Units)
Figure 31. Angiogenesis Modulators Consumed in Colorectal Cancer
Figure 32. Global Angiogenesis Modulators Market: Colorectal Cancer (2021-2026) & (K Units)
Figure 33. Angiogenesis Modulators Consumed in Lung Cancer
Figure 34. Global Angiogenesis Modulators Market: Lung Cancer (2021-2026) & (K Units)
Figure 35. Angiogenesis Modulators Consumed in Prostate Cancer
Figure 36. Global Angiogenesis Modulators Market: Prostate Cancer (2021-2026) & (K Units)
Figure 37. Angiogenesis Modulators Consumed in Others
Figure 38. Global Angiogenesis Modulators Market: Others (2021-2026) & (K Units)
Figure 39. Global Angiogenesis Modulators Sale Market Share by Application (2025)
Figure 40. Global Angiogenesis Modulators Revenue Market Share by Application in 2025
Figure 41. Angiogenesis Modulators Sales by Company in 2025 (K Units)
Figure 42. Global Angiogenesis Modulators Sales Market Share by Company in 2025
Figure 43. Angiogenesis Modulators Revenue by Company in 2025 ($ millions)
Figure 44. Global Angiogenesis Modulators Revenue Market Share by Company in 2025
Figure 45. Global Angiogenesis Modulators Sales Market Share by Geographic Region (2021-2026)
Figure 46. Global Angiogenesis Modulators Revenue Market Share by Geographic Region in 2025
Figure 47. Americas Angiogenesis Modulators Sales 2021-2026 (K Units)
Figure 48. Americas Angiogenesis Modulators Revenue 2021-2026 ($ millions)
Figure 49. APAC Angiogenesis Modulators Sales 2021-2026 (K Units)
Figure 50. APAC Angiogenesis Modulators Revenue 2021-2026 ($ millions)
Figure 51. Europe Angiogenesis Modulators Sales 2021-2026 (K Units)
Figure 52. Europe Angiogenesis Modulators Revenue 2021-2026 ($ millions)
Figure 53. Middle East & Africa Angiogenesis Modulators Sales 2021-2026 (K Units)
Figure 54. Middle East & Africa Angiogenesis Modulators Revenue 2021-2026 ($ millions)
Figure 55. Americas Angiogenesis Modulators Sales Market Share by Country in 2025
Figure 56. Americas Angiogenesis Modulators Revenue Market Share by Country (2021-2026)
Figure 57. Americas Angiogenesis Modulators Sales Market Share by Type (2021-2026)
Figure 58. Americas Angiogenesis Modulators Sales Market Share by Application (2021-2026)
Figure 59. United States Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 60. Canada Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 61. Mexico Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 62. Brazil Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 63. APAC Angiogenesis Modulators Sales Market Share by Region in 2025
Figure 64. APAC Angiogenesis Modulators Revenue Market Share by Region (2021-2026)
Figure 65. APAC Angiogenesis Modulators Sales Market Share by Type (2021-2026)
Figure 66. APAC Angiogenesis Modulators Sales Market Share by Application (2021-2026)
Figure 67. China Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 68. Japan Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 69. South Korea Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 70. Southeast Asia Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 71. India Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 72. Australia Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 73. China Taiwan Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 74. Europe Angiogenesis Modulators Sales Market Share by Country in 2025
Figure 75. Europe Angiogenesis Modulators Revenue Market Share by Country (2021-2026)
Figure 76. Europe Angiogenesis Modulators Sales Market Share by Type (2021-2026)
Figure 77. Europe Angiogenesis Modulators Sales Market Share by Application (2021-2026)
Figure 78. Germany Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 79. France Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 80. UK Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 81. Italy Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 82. Russia Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 83. Middle East & Africa Angiogenesis Modulators Sales Market Share by Country (2021-2026)
Figure 84. Middle East & Africa Angiogenesis Modulators Sales Market Share by Type (2021-2026)
Figure 85. Middle East & Africa Angiogenesis Modulators Sales Market Share by Application (2021-2026)
Figure 86. Egypt Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 87. South Africa Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 88. Israel Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 89. Turkey Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 90. GCC Countries Angiogenesis Modulators Revenue Growth 2021-2026 ($ millions)
Figure 91. Manufacturing Cost Structure Analysis of Angiogenesis Modulators in 2026
Figure 92. Manufacturing Process Analysis of Angiogenesis Modulators
Figure 93. Industry Chain Structure of Angiogenesis Modulators
Figure 94. Channels of Distribution
Figure 95. Global Angiogenesis Modulators Sales Market Forecast by Region (2027-2032)
Figure 96. Global Angiogenesis Modulators Revenue Market Share Forecast by Region (2027-2032)
Figure 97. Global Angiogenesis Modulators Sales Market Share Forecast by Type (2027-2032)
Figure 98. Global Angiogenesis Modulators Revenue Market Share Forecast by Type (2027-2032)
Figure 99. Global Angiogenesis Modulators Sales Market Share Forecast by Application (2027-2032)
Figure 100. Global Angiogenesis Modulators Revenue Market Share Forecast by Application (2027-2032)